Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 2/20 | 0.40 |
| ▸ | METAP2 | P50579 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4993384 | 0.99 | REN (0.38) | RENMETAP2ALDH1A1CPB2LTA4H | |
| SCHEMBL4987808 | 0.96 | REN (0.36) | RENMETAP2ALDH1A1CPB2LTA4H | |
| SCHEMBL4981462 | 0.93 | ANPEP (0.36) | REN | |
| SCHEMBL4986842 | 0.87 | METAP2 (0.41) | RENMETAP2ALDH1A1LTA4HATM | |
| SCHEMBL4989904 | 0.86 | METAP2 (0.41) | RENMETAP2ALDH1A1METAP1FFAR1 | |
| SCHEMBL4989377 | 0.85 | METAP2 (0.39) | RENMETAP2ALDH1A1LTA4HATM | |
| SCHEMBL4984122 | 0.85 | METAP2 (0.39) | RENMETAP2ALDH1A1METAP1 | |
| SCHEMBL4991309 | 0.84 | REN (0.40) | RENMETAP2ALDH1A1CPB2LTA4H | |
| SCHEMBL4993726 | 0.82 | REN (0.38) | RENMETAP2ALDH1A1CPB2LTA4H | |
| SCHEMBL4989753 | 0.82 | METAP2 (0.37) | RENMETAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1886363-A | Amino acids with affinity for the alpha2delta-protein | WARNER LAMBERT CO (US) | 2006-12-27 | — | — | CN | claimed |
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | claimed |
| US-7388023-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2008-06-17 | — | — | US | disclosed |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WANER-LAMBERT COMPANY LLC (US) | 2007-06-07 | — | — | US | disclosed |
| US-7179934-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-20 | — | — | US | disclosed |
| CN-1886363-A | Amino acids with affinity for the alpha2delta-protein | WARNER LAMBERT CO (US) | 2006-12-27 | — | — | CN | disclosed |
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | disclosed |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, SCN1A, OPRD1 | REN 3028/4885METAP2 1352/4885ALDH1A1 1484/4885 |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | SCN2A, OPRD1, SCN1A | REN 2682/4885METAP2 1042/4885ALDH1A1 1627/4885 |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | REN 2912/4885METAP2 1060/4885ALDH1A1 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.